Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The threshold-suspend feature of sensor-augmented insulin pumps is designed to minimize the risk of hypoglycemia by interrupting insulin delivery at a preset sensor glucose value. We evaluated sensor-augmented insulin-pump therapy with and without the threshold-suspend feature in patients with nocturnal hypoglycemia. METHODS: We randomly assigned patients with type 1 diabetes and documented nocturnal hypoglycemia to receive sensor-augmented insulin-pump therapy with or without the threshold-suspend feature for 3 months. The primary safety outcome was the change in the glycated hemoglobin level. The primary efficacy outcome was the area under the curve (AUC) for nocturnal hypoglycemic events. Two-hour threshold-suspend events were analyzed with respect to subsequent sensor glucose values. RESULTS: A total of 247 patients were randomly assigned to receive sensor-augmented insulin-pump therapy with the threshold-suspend feature (threshold-suspend group, 121 patients) or standard sensor-augmented insulin-pump therapy (control group, 126 patients). The changes in glycated hemoglobin values were similar in the two groups. The mean AUC for nocturnal hypoglycemic events was 37.5% lower in the threshold-suspend group than in the control group (980 ± 1200 mg per deciliter [54.4 ± 66.6 mmol per liter] × minutes vs. 1568 ± 1995 mg per deciliter [87.0 ± 110.7 mmol per liter] × minutes, P<0.001). Nocturnal hypoglycemic events occurred 31.8% less frequently in the threshold-suspend group than in the control group (1.5 ± 1.0 vs. 2.2 ± 1.3 per patient-week, P<0.001). The percentages of nocturnal sensor glucose values of less than 50 mg per deciliter (2.8 mmol per liter), 50 to less than 60 mg per deciliter (3.3 mmol per liter), and 60 to less than 70 mg per deciliter (3.9 mmol per liter) were significantly reduced in the threshold-suspend group (P<0.001 for each range). After 1438 instances at night in which the pump was stopped for 2 hours, the mean sensor glucose value was 92.6 ± 40.7 mg per deciliter (5.1 ± 2.3 mmol per liter). Four patients (all in the control group) had a severe hypoglycemic event; no patients had diabetic ketoacidosis. CONCLUSIONS: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values. (Funded by Medtronic MiniMed; ASPIRE ClinicalTrials.gov number, NCT01497938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“People with diabetes who continue to have frequent and severe hypoglycemia and/or impaired awareness of hypoglycemia, despite educational interventions, may benefit from continuous subcutaneous insulin infusion (CSII) therapy or continuous glucose monitoring (CGM) or both (i.e. a sensor augmented pump), to reduce the risk of severe hypoglycemia (44)(45)(46)(47).”
From Hypoglycemia (2018) · cites this paper as [46]
In the citing paper
“Insulin pumps with automated low-glucose suspend and automated insulin delivery systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (126).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [126]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [24]
In the citing paper
“CGM with automated low glucose suspend and hybrid closed-loop systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (95).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [95]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Fear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579
Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes
Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3592 · Cited by 401
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Towler, D. A., Havlin, C. E., Craft, S., & Cryer, P. (1993) · Diabetes · doi:10.2337/diab.42.12.1791 · Cited by 258
Tanenberg, R. J., Newton, C. A., & Drake, A. J. (2010) · Endocrine Practice · doi:10.4158/ep09260.cr · Cited by 225
Increasing the sample size when the unblinded interim result is promising
Chen, Y. H. J., DeMets, D. L., & Gordon Lan, K. K. (2004) · Statistics in Medicine · doi:10.1002/sim.1688 · Cited by 207
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Cited by
Items 601–662 of 662
Burn, M. S., Burn, S. C., & Burn, P. (2019) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2019.06.00182
WEINZIMER, S. A., CARRIA, L. R., & Name, M. A. V. (2021) · Contemporary Endocrinology · doi:10.1007/978-3-030-64133-7_8
ISPAD Clinical Practice Consensus Guidelines 2018. Managing diabetes in preschool children
Зелінська, П. Н. Б. (2021) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/ujpe2021-2-35
Evolution of Glycemic Targets in Management of Diabetes
Masood, M. Q. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115018
Does HbA1c Remain the Most Important Therapeutic Target in Outpatient Management of Diabetes?
Gonzales, K. M., & Smith, S. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch8
Fezzi, C., Refahi, H., Albuisson, É., & Feigerlová, E. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3969853
Sensorunterstützte Pumpentherapie: Mehr Sicherheit durch automatische Abschaltung
Hahne, D. (2015) · Deutsches Ärzteblatt · doi:10.3238/persdia.2015.10.23.09
Romeo, G. R., Silva, P. S., & Cavallerano, J. D. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_294-1
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Lamos, E. M., Younk, L. M., & Davis, S. N. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch31
Therapy of Type 1 Diabetes Mellitus
Omura, E., & Peters, A. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-1
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_43
Pickup, J. C. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_22
mHealth Environments for Chronic Disease Management
Georga, E. I., Papadopoulos, A. N., & Fotiadis, D. I. (2017) · IGI Global eBooks · doi:10.4018/978-1-5225-2237-9.ch038
花﨑, 和., 北川博之, 上村, 直., 宗景匡哉, 藤澤和音, & 努, 並. (2018) · The Japanese Journal of SURGICAL METABOLISM and NUTRITION · doi:10.11638/jssmn.52.2_145
mHealth Environments for Chronic Disease Management
Georga, E. I., Papadopoulos, A. N., & Fotiadis, D. I. (2018) · IGI Global eBooks · doi:10.4018/978-1-5225-6915-2.ch030
Diabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., & Shalitin, S. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.2507 · Cited by 1
Successes and Disappointments with Clinical Islet Transplantation
Cravedi, P., Ruggenenti, P. L., & Remuzzi, G. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_23
Bishop, D. B., O’Connor, P. J., Kidney, R. S. M., & Haire-Joshu, D. L. (2016) · American Public Health Association eBooks · doi:10.2105/9780875532783ch12
Type 1 diabetes: technology and transplants
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch8
Hypoglykämie bei Kindern und Jugendlichen
Schwab, K. O., & Doerfer, J. (2018) · Springer Reference Medizin · doi:10.1007/978-3-662-52794-8_13-1
Carty, D. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch10
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00936-y
Evolving Approaches to Type 1 Diabetes Management
Skyler, J. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_16
宗景, 匡. (2022) · JAPANES JOURNAL OF MEDICAL INSTRUMENTATION · doi:10.4286/jjmi.92.348
Chapter 26: Diabetes Technologies
Tomky, D. M. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580405690.ch26
Shah, V. N., Michels, A. W., & Garg, S. K. (2015) · American Diabetes Association eBooks · doi:10.2337/9781580405713.case88
Self-citationDiabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1
Rami-Merhar, B. M. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00975-5
Reinhart-Steininger, B., Schütz-Fuhrmann, I., & Stulnig, T. M. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00184-x
“Ist die Insulinpumpe mit einem Glukosesensor gekoppelt, wird bei entsprechendenPumpensystemen imFalle einer drohenden Hypoglykämie die Basalrate – mit und ohne Alarmfunktion – automatischunterbrochen,wodurcheineUnterzuckerung zumeist verhindert werden kann [7, 8] („predictive low-glucose suspend“, PLGS).”
BackgroundUsing Diabetes Technology to Maximize Diabetes Management
Young, C. F., Wong, S. M., & Vanderwyk, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95884-4.00006-8
Stem Cell Therapy in Diabetes Mellitus
Saeed, A. G., & Sebaiy, M. M. (2023) · Journal of Clinical and Medical Reviews · doi:10.58489/2836-2330/013
Verso il pancreas artificiale: i sistemi ibridi ad ansa chiusa
Molfetta, S. D., de Candia, S., Giorgino, F., & Laviola, L. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01318-2
Elhenawy, Y. I., Shaarawy, M. A., & Selim, E. M. (2023) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2023-0250
Iqbal, A., Chow, E., Jones, T. W., & Heller, S. R. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch40
Controlling Human Physiology via Drugs and Devices
Hahn, J., & Howsmon, D. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14081-5.00009-x
Data analytic models of patients dependent on insulin treatment
Adetuyi, T. G., Adetuyi, B. O., Okunlola, F. O., Oni, P. G., Olajide, P. A., Omolehin, P. T., Adetunji, C. O., Adetunji, M. C., & Oyewole, O. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95686-4.00017-4
(2024) · American Diabetes Association eBooks · doi:10.2337/9781580408363.ch05
宗景, 匡. (2024) · The Japanese Journal of SURGICAL METABOLISM and NUTRITION · doi:10.11638/jssmn.58.6_204
Cengiz, E. (2019) · doi:10.2337/9781580406932.part1_ch03
Enhancing Diabetes Management Through the Integration of CGM and Insulin Pumps
Zhang, M. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.21498
Advances in beta-cell replacement therapies for type 1 diabetes mellitus: A narrative review
Jalaludeen, A., & Sinha, S. (2025) · Journal of Indira Gandhi Institute Of Medical Sciences · doi:10.4103/jigims.jigims_61_24
An overview on recent developments in insulin pump therapy with a regional perspective
Muzammil, F. M., shehzad, H., Shriya, S. R., Tayb, T., Iqbal, Y., & Houni, A. E. (2025) · Journal of Research in Clinical Medicine · doi:10.34172/jrcm.025.34767
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Danne, T., Freckmann, G., Kautzky‐Willer, A., Lang, U. E., Lehmann, R., Pfohl, M., Schloot, N. C., & Schumm‐Draeger, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-41358-2_3
Contrôle glycémique informatisé en réanimation
Kalfon, P. (2014) · theses.fr (ABES) · doi:10.70675/1b614db6z9eaaz4fcfzb93czfe1b424d1540
Dreyer, M. (2014) · Der Diabetologe · doi:10.1007/s11428-013-1193-1
Pitoglou, S. (2024) · DSpace - NTUA (National Technical University of Athens) · doi:10.26240/heal.ntua.26597
Proietti, A., & Grosembacher, L. (2015) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/rev.hosp.ital.b.aires.v35i2.731
Gros, P. (2024) · Repository of the University of Primorsk (University of Primorska)
Artificial Intelligence in Personalized Insulin Therapy for Diabetes Mellitus
Bhoyar, P. K., & Yadav, P. J. (2026) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/25dec1286
Approach to the Hypoglycemic Patient
Chang, M., & Willis, G. C. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.02.004
A Review on Hybrid Closed Loop Insulin Delivery System
Kuralarasan, S. G. (2025) · Advances in Applied Biological Research · doi:10.48165/aabr.2025.2.2.04
Guilmin‐Crépon, S. (2019) · theses.fr (ABES) · doi:10.70675/5899a8c0z309fz4054zb769z5131506531f0
Diabetestechnologie (Update 2026)
Schütz-Fuhrmann, I., Rami-Merhar, B. M., Hofer, S. E., Fröhlich-Reiterer, E. E., Tauschmann, M., Mader, J. K., Resl, M., Kautzky‐Willer, A., Winhofer-Stöckl, Y., Wascher, T. C., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02630-7
“Durch die Verwendung von Insulinpumpen und Glukosesensoren werden niedrigere HbA 1c -Werte und eine höhere TIR erreicht, ohne dabei das Hypoglyk-ämierisiko zu erhöhen [22].”
InfluentialYoo, J., Rachim, V. P., Lee, Y., Lee, J., & Park, S.-J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.25.727637
Yamaoka, T., Sugiyama, T., Kashiwagi, K., Furuno, T., Yamamoto, K., Imai, K., Ihana‐Sugiyama, N., Nishioka, Y., Ohsugi, M., Ueki, K., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113462
Digital Health Technologies and Hypoglycaemia
Villard, O., & Renard, É. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_24
Current options in insulin pump therapy for diabetes
Radovnická, L. (2026) · Klinická farmakologie a farmacie · doi:10.36290/far.2026.020
Georga, E. I., Protopappas, V. C., Bellos, C. V., Makriyiannis, D., & Fotiadis, D. I. (2013) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-319-03005-0_80
Untitled work
Diabetes Canada Clinical Practice Guidelines Expert Committee (n.d.) · Diabetes Canada
Metadata
- Authors
- Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R.
- Affiliations
- Park Nicollet Health Services (US)
- Mills Peninsula Health Services (US)
- University of Colorado Denver (US)
- Atlanta Diabetes Associates (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 224-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102877966
- Cited by
- 652
- References
- 21
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 18 · 2023: 36 · 2022: 30 · 2021: 41 · 2020: 39 · 2019: 62 · 2018: 75 · 2017: 80 · 2016: 82 · 2015: 74 · 2014: 73 · 2013: 17
- FWCI
- 64.50
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Repositorio Institucional (Pontificia Universidad Javeriana) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- sensor-augmented pump, insulin pump therapy, nocturnal hypoglycemia, type 1 diabetes, HbA1c, hypoglycemia prevention, continuous glucose monitoring, glycemic control, hypoglycemic events, hypoglycemia severity, hypoglycemia duration
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Area Under Curve, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.